The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: immune thrombocytopenia purpura (ITP) following therapy with an immune checkpoint inhibitor
Parameter:
(1) platelet count per microliter
|
Parameter
|
Finding
|
Grade
|
|
platelet count
|
75,000 - 100,000 per µL
|
G1
|
|
|
50,000 - 74,999 per µL
|
G2
|
|
|
25,000 - 49,999 per µL
|
G3
|
|
|
< 25,000 per µL
|
G4
|
where:
• The lower limit of normal for the platelet count is usually around 150,000 per µL. The cutoff for G1 could be raised.
The diagnosis requires exclusion of:
(1) other causes of thrombocytopenia
(2) other thrombocytopenic disorders caused by the immune checkpoint inhibitors (TTP, HUS)
